je.st
news
Tag: pfizers
EU regulators clear Pfizer's purchase of Hospira
2015-08-04 21:36:15| Biotech - Topix.net
" European Union regulators on Tuesday approved Pfizer's $15.23 billion purchase of injectable drug and infusion device maker Hospira. The European Commission said Pfizer agreed to sell the European rights to experimental biosimilar version of the immune disorder drug Remicade and a few other products, including some chemotherapy drugs, in certain markets.
Tags: clear
purchase
regulators
hospira
Pfizer's revenue, Profit Beat As Vaccine Sales Rise
2015-07-29 09:08:28| Biotech - Topix.net
Pfizer Inc reported better-than-expected quarterly profit and revenue, helped by strong demand for its pneumonia vaccine Prevnar 13 and sales of its breast cancer drug, Ibrance. The company, which also raised its full-year adjusted earnings forecast, said revenue from its global vaccines unit rose 44 percent to $1.58 billion.
Pfizer's RAPAMUNE (sirolimus) Becomes First FDA-Approved Treatment For Lymphangioleiomyomatosis (LAM), A Rare Progressive Lung Disease
2015-06-03 06:19:12| drugdiscoveryonline Home Page
Pfizer Inc. announced recently that the U.S. Food and Drug Administration (FDA) has approved RAPAMUNE (sirolimus) for the treatment of lymphangioleiomyomatosis (LAM), a rare, progressive disease that affects the lungs, kidneys and the lymphatic system
Tags: treatment
disease
rare
progressive
Pfizer's Ibrance drug slows progression of breast cancer
2015-05-30 19:03:57| Biotech - Topix.net
CHICAGO: A Phase III trial of Pfizer Inc's drug Ibrance showed that, in combination with hormone therapy, the drug more than doubled the duration of disease control for women with the most common type of breast cancer. At the time of an interim analysis, patients given Ibrance in combination with AstraZeneca Plc's Faslodex , a widely used treatment to block estrogen, lived an average of 9.2 months before their cancer worsened.
Tags: drug
cancer
breast
progression
Pfizer's Strong FCF Means Big Dividend Growth
2015-03-07 06:38:46| Biotech - Topix.net
Healthcare juggernaut Pfizer has seen its shares post new multi-year highs of late as optimism from investors is evidenced through strong buying activity. This rally has ended a long period of consolidation as PFE's business stalled.